TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor-infiltrating lymphocytes has shown to positively cor...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncoimmunology
Main Authors: Maas, Ralph Ja, Hoogstad-van Evert, Janneke S, Van der Meer, Jolien Mr, Mekers, Vera, Rezaeifard, Somayeh, Korman, Alan J, de Jonge, Paul Kjd, Cany, Jeannette, Woestenenk, Rob, Schaap, Nicolaas Pm, Massuger, Leon F, Jansen, Joop H, Hobo, Willemijn, Dolstra, Harry
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2020
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657585/
https://ncbi.nlm.nih.gov/pubmed/33224630
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1843247
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares